Solventum Corporation $SOLV Shares Sold by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ lessened its holdings in shares of Solventum Corporation (NYSE:SOLV) by 51.6% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 32,513 shares of the company’s stock after selling 34,654 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in Solventum were worth $2,466,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in SOLV. Sumitomo Mitsui DS Asset Management Company Ltd increased its stake in Solventum by 0.7% in the second quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,778 shares of the company’s stock valued at $1,500,000 after purchasing an additional 140 shares during the last quarter. Tradition Wealth Management LLC boosted its holdings in shares of Solventum by 1.6% in the 1st quarter. Tradition Wealth Management LLC now owns 8,830 shares of the company’s stock valued at $671,000 after buying an additional 143 shares in the last quarter. Applied Finance Capital Management LLC grew its position in shares of Solventum by 3.8% in the 2nd quarter. Applied Finance Capital Management LLC now owns 4,428 shares of the company’s stock valued at $336,000 after buying an additional 162 shares during the last quarter. SouthState Corp raised its stake in Solventum by 31.9% during the 1st quarter. SouthState Corp now owns 699 shares of the company’s stock worth $53,000 after acquiring an additional 169 shares in the last quarter. Finally, HB Wealth Management LLC lifted its position in Solventum by 5.6% in the second quarter. HB Wealth Management LLC now owns 3,463 shares of the company’s stock valued at $263,000 after acquiring an additional 185 shares during the last quarter.

Analyst Upgrades and Downgrades

SOLV has been the topic of several research reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Solventum in a report on Thursday, October 30th. Piper Sandler raised their price target on Solventum from $94.00 to $98.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Wall Street Zen cut Solventum from a “buy” rating to a “hold” rating in a research note on Monday. UBS Group reissued a “neutral” rating on shares of Solventum in a report on Friday, November 21st. Finally, Zacks Research raised shares of Solventum from a “hold” rating to a “strong-buy” rating in a report on Monday, September 15th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Solventum currently has an average rating of “Hold” and a consensus target price of $85.56.

Solventum Trading Up 0.4%

Shares of SOLV stock opened at $85.57 on Tuesday. The company has a market capitalization of $14.84 billion, a P/E ratio of 9.86, a price-to-earnings-growth ratio of 9.00 and a beta of 0.25. The company has a current ratio of 1.50, a quick ratio of 1.14 and a debt-to-equity ratio of 1.03. The business’s 50 day moving average is $74.01 and its two-hundred day moving average is $73.75. Solventum Corporation has a twelve month low of $60.70 and a twelve month high of $86.81.

Solventum (NYSE:SOLV) last issued its quarterly earnings results on Thursday, November 6th. The company reported $1.50 earnings per share for the quarter, topping the consensus estimate of $1.43 by $0.07. Solventum had a return on equity of 28.01% and a net margin of 18.13%.The firm had revenue of $2.10 billion during the quarter, compared to the consensus estimate of $2.05 billion. During the same period last year, the company earned $1.64 earnings per share. The company’s revenue for the quarter was up .7% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. Equities analysts forecast that Solventum Corporation will post 6.58 EPS for the current year.

Solventum announced that its board has approved a stock buyback program on Thursday, November 20th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the company to buy up to 7.5% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board believes its shares are undervalued.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.